
(AGENPARL) – SILVER SPRING ven 12 maggio 2023 The FDA approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause.
Fonte/Source: http://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause